BioSpace News Archive

Skyland Analytics announced that REGENXBIO has selected Skyland PIMS Process Information Management Suite for management and analysis of product, process and patient data throughout their development and manufacturing supply chain.

SpringWorks Therapeutics, Inc. announced that the U.S. Food and Drug Administration has granted Fast Track designation for PD-0325901, an investigational, oral, small molecule inhibitor of MEK1 and MEK2, for the treatment of patients ≥ 2 years of age with neurofibromatosis type 1-associated inoperable plexiform neurofibromas that are progressing or causing significant morbidity.

Indianapolis-based neurosurgical medical device maker NICO Corporation continued its international expansion in the European Union by holding its inaugural 2-day international course in Granada, Spain during the World Intracranial Hemorrhage Conference.

New survey reveals nearly three in four Americans say that talking to a close family member about cognitive decline would be challenging

NanoViricides, Inc. a company with novel platform technology to fulfill unmet medical needs in treating difficult and life-threatening viral diseases, reports that it has received favorable comments from the US FDA on the Company’s pre-IND application for its lead drug candidate.

Proteostasis Therapeutics, Inc. announced that data from the Company’s CF clinical development programs will be presented during three panel presentations at the 42nd European Cystic Fibrosis Society Conference on June 5-8, 2019 at the Arena and Convention Centre Liverpool in Liverpool, United Kingdom.

AcelRx Pharmaceuticals, Inc. announced the closing of a $25 million senior secured debt facility with Oxford Finance LLC, a specialty finance firm providing senior debt to life sciences and healthcare services companies worldwide.

Sierra Oncology, Inc. is holding an analyst and investor event featuring distinguished oncologists Professor Johann de Bono and Dr. Rebecca Kristeleit, to discuss clinical findings and possible next steps for its oral, highly selective Chk1 inhibitor, SRA737.

QED Therapeutics announced the presentation of data demonstrating the clinical activity of its investigational product infigratinib in advanced or metastatic upper tract urothelial carcinoma compared to urothelial carcinoma of the bladder.

Franz-Ulrich Hartl and Arthur Horwich Named 2019 Dr. Paul Janssen Award Winners for Revolutionary Insights into the Fundamental Molecular Process of Protein Folding